Search

Displaying results 3441 - 3450 of 8010 in total
  1. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  2. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … [A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine

  3. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway. … and other lipids from cells including those in the arterial wall.

  4. Drug

    MK-0731

    go.drugbank.com/drugs/DB08037
    Investigational

    MK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.

  5. Drug

    Tagatose

    go.drugbank.com/drugs/DB04936
    Investigational

    Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes. … It is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Trials were halted in the U.S., but the drug is used in various countries.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.

  8. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

  9. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax. … [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior

  10. Drug

    MK-4965

    go.drugbank.com/drugs/DB08460
    Experimental

    MK-4965 is an HIV-1 reverse transcriptase inhibitor.